Sponsor Dossier
Actor Pharmaceuticals
Sponsor Dossier for Actor Pharmaceuticals. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ACTARIN
- Brand: ACTAVANZ
- Brand: ACTOBET
- Brand: ACTOSTARIN
- Brand: AFLIVU
- Brand: AHZANTIVE
- Brand: ANDRIGA-10
- Brand: ANDRIGA-5
- Device (sponsor): Non-sterile scar management dressing, reusable
- Device (sponsor): Nasal breathing aid, external
- Device (sponsor): Wart cryogenic kit
- Device (sponsor): Excilor Warts 2 in 1 Warts Treatment - Wart cryogenic kit
- Device (sponsor): Nail treatment solution
- Device (sponsor): Nail treatment solution
About
Actor Pharmaceuticals is an Australian Private Company with ABN 69 151 192 602, registered in NSW and currently active.
Portfolio
Actor Pharmaceuticals has 28 brands on the ARTG, of which 8 are indexable and 7 carry a Product Information document. 3 brands are PBS-listed, 2 have a PBAC outcome on record, and 4 have an AusPAR on record. Notable brands include ACTARIN, ACTAVANZ, ACTOBET, ACTOSTARIN, AFLIVU, AHZANTIVE, ANDRIGA-10, ANDRIGA-5, APIXABAN, AXHIDROX, AXORAN, CALCIPBETA.
Therapeutic focus
— Dermatology: 6 brands — Complementary Medicine: 5 brands — Haematology: 3 brands — Ophthalmology: 3 brands — Cardiology: 2 brands — Oncology: 2 brands — Reproductive Health: 2 brands — Psychiatry: 1 brand — Gastroenterology: 1 brand — Respiratory: 1 brand — Pain Management: 1 brand — Neurology: 1 brand
PBS footprint
3 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2025-11-01, across 2 brands with a PBAC outcome on record. The latest AusPAR is 2026-03-27, across 4 brands with an AusPAR on record.